Orexin Agents ORX750 and ORX142 Show Promising Early Phase 1 and 2 Data Marco Meglio

Published Date: 21 Nov 2025

Centessa Pharmaceuticals reveals promising early-stage results for its orexin receptor 2 agonists, ORX750 and ORX142, targeting neurologic sleep disorders.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Geriatric Assessment, QoL Correlate With OS in Older Patients with Pancreatic Cancer

2.

Higher Binge Drinking Rates Linked to New Cannabis Laws.

3.

Cancer Patients Who Completed Medication Survey Received More Help From Pharmacists

4.

Ketamine plus psychotherapy for "excellent" PTSD

5.

No Seed Oil-Colon Cancer Link; Avoiding Prostate Biopsy; Top Cancer Advances


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot